Clinical Trial Update: Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing lot consistency, immunogenicity, and safety of the meningococcal vaccine GSK134612 given with Fluarix in adults aged 18-55; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Fluarix (influenza vaccine)
• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2012-05-22